Chondrosarcoma - Pipeline Insight, 2021
SKU ID :DEL-17687673 | Published Date: 15-Mar-2021 | No. of pages: 60Description
TOC
Introduction
Executive Summary
Chondrosarcoma: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Chondrosarcoma – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Chondrosarcoma companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Chondrosarcoma Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
INBRX-109: Inhibrx
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
• Comparative Analysis
Ifosfamide: Atlanthera
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Chondrosarcoma Key Companies
Chondrosarcoma Key Products
Chondrosarcoma- Unmet Needs
Chondrosarcoma- Market Drivers and Barriers
Chondrosarcoma- Future Perspectives and Conclusion
Chondrosarcoma Analyst Views
Chondrosarcoma Key Companies
Appendix
Tables & Figures
Table 1 Total Products for Chondrosarcoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Companies
• Roche
• ImmunityBio
• Inhibrx
• AnHeart Therapeutics
• Atlanthera
- PRICE
-
$1500$4500